AstraZeneca Announces U.S. Enrollment Opportunities for KODIAC Study to Investigate an Experimental Drug for Constipation from Opioids

AstraZeneca AZN today announced that study centers across the U.S. are recruiting patients for a clinical study to examine whether an investigational drug is safe and effective in treating opioid-induced constipation. The study, known as KODIAC, is a Phase III clinical trial examining an investigational drug in patients experiencing constipation as a result of opioid use, which is a potential side effect of prescription opioid pain medications.